A large number of chemical agents are known which affect blood and blood-forming organs. The purpose of this volume is to review the sig nificant advances made over the past several years regarding such chemical agents. The purification, biological action, and therapeutic implications of several widely used hematopoietic growth factors such as interleukin 3 (IL-3 or multi-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), colony stimu lating factor (CSF-I or M-CSF), thrombopoietin, and erythropoietin are included in this volume.…mehr
A large number of chemical agents are known which affect blood and blood-forming organs. The purpose of this volume is to review the sig nificant advances made over the past several years regarding such chemical agents. The purification, biological action, and therapeutic implications of several widely used hematopoietic growth factors such as interleukin 3 (IL-3 or multi-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), colony stimu lating factor (CSF-I or M-CSF), thrombopoietin, and erythropoietin are included in this volume. These factors are important in regulating several hematopoietic cell lines such as neutrophils, monocytes, eosinophils, macrophages, megakaryocytes, platelets, and erythrocytes. People are exposed daily to numerous toxic chemical substances present in our environment which produce a suppression of erythropoiesis, myelo poiesis, lymphocytopoiesis, and megakaryocytopoiesis. Attempts have been madein this volume to assess the therapeutic role of some of the hematopoietic factors such as erythropoietin in the anemia of end stage renal disease, as well as colony stimulating factors in other hematopoietic abnormalities. In addition, some of the chemical factors in our environment which suppress major hematopoietic lineages stimulated by erythropoietin, macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin I-alpha, interleukin I-beta, and interleukins 2, 3, 4, 5, 6, 7, and 9 are also included. An updating of the mechanism of action of each of these factors on the major hematopoietic lineages is covered.
How do certain substances, known as growth factors, cause blood to be built in the human body? In what way do the chemicals we are exposed to every day affect the blood-building system? Cell biologists and hematologists will find the latest answers in this volume.
Inhaltsangabe
1 Introduction.- 2 Fundamental Control of Hematopoiesis.- A. Introduction.- B. Hierarchical Organization of Hematopoietic Cells.- C. Assay and Characterization of In Vitro Clonogenic Cells.- D. Use of In Vitro Clonogenic Cell Assays.- E. Newer Assays for More Primitive Cells.- F. Regulatory Mechanisms.- G. Future Outlook.- References.- 3 Kidney Regulation of Erythropoietin Production.- A. Introduction.- B. Model for the Control of Erythropoietin Production.- C. Hypoxia and Erythropoietin Production.- D. Adenosine and Erythropoietin Production.- References.- 4 The Mechanism of Action of Erythropoietin: Erythroid Cell Response.- A. Introduction.- B. Model Systems for Studying the Interaction of Erythropoietin with Erythroid Progenitor Cells.- C. Interaction of Other Growth and Development Factors with Erythroid Progenitor Cells.- D. The Erythroid Differentiation Program.- E. Signal Transduction in Erythroid Progenitor Cells.- F. Erythropoietin as a Competence or Progression Factor.- G. Conclusion.- References.- 5 The Arachidonic Acid Cascade and Erythropoiesis.- A. Introduction.- B. Evidence for the Roles of Arachidonic Acid Metabolism in Erythropoiesis.- C. Future Directions for Research.- References.- 6 Iron Deficiency and Megaloblastic Anemias.- A. Iron-Deficiency Anemia.- B. Megaloblastic Anemias.- References.- 7 Erythropoietin in the Anemia of End-Stage Renal Disease.- A. Assay of Erythropoietin.- B. Pathogenesis of the Anemia of Chronic Renal Failure.- C. Kidney Production of Erythropoietin.- D. Erythropoietin in Therapy of Renal Anemia.- E. Conclusions.- References.- 8 Humoral Control of Thrombocytopoiesis.- A. Introduction.- B. Model for Megakaryocytopoiesis.- C. Controlling Factors.- D. Other Factors Affecting Thrombocytopoiesis.- E. Clinical Aspects of Thrombopoietin.- F. Future of Thrombopoietin.- References.- 9 Arachidonic Acid Metabolism Platelets and Thromboembolic Disease.- A. Arachidonic Acid Metabolism.- B. Thromboembolic Disease.- C. Concluding Comments.- References.- 10 Chemical Agents That Inhibit Platelet Aggregation.- A. Introduction.- B. Platelet Physiology.- C. Platelet Structure.- D. Platelet Involvement in Thrombosis.- E. Platelet Responses.- F. Inhibition of Platelet Aggregation.- G. Conclusions.- References.- 11 Anticoagulants, Antithrombotic and Thrombolytic Agents.- A. Anticoagulants.- B. Thrombolytic Therapy.- C. Antithrombotic Therapy.- References.- 12 Granulocyte-Macrophage Growth Factors.- A. Introduction.- B. Historical Background.- C. Growth Factors.- D. Other Interleukins.- E. Inhibitors.- F. Cellular Production and Networking.- G. Microenvironment.- H. Conclusions.- References.- 13 Chemical Agents Which Suppress Myelopoiesis: Agranulocytosis and Leukemia.- A. Introduction.- B. Normal Marrow Cell Kinetics.- C. Pathophysiologic Mechanisms for Drug-Induced Neutropenia.- D. Neutropenia Associated with Cytotoxic Chemotherapeutic Agents.- E. Drug-Induced Myeloid Suppression.- F. Idiosyncratic Neutropenias.- G. Pseudoneutropenia.- H. Secondary Leukemia.- J. Conclusions.- References.- 14 Drugs Useful in the Chemotherapy of the Acute Leukemias.- A. Introduction.- B. Antimetabolites.- C. Drugs that Intercalate in DNA.- D. Podophyllotoxin Derivatives.- E. Vinca Alkaloids.- F. Alkylating/DNA Binding Agents.- G. Adrenal Glucocorticoids.- H. Enzymes.- J. Multidrug Resistance.- References.
1 Introduction.- 2 Fundamental Control of Hematopoiesis.- A. Introduction.- B. Hierarchical Organization of Hematopoietic Cells.- C. Assay and Characterization of In Vitro Clonogenic Cells.- D. Use of In Vitro Clonogenic Cell Assays.- E. Newer Assays for More Primitive Cells.- F. Regulatory Mechanisms.- G. Future Outlook.- References.- 3 Kidney Regulation of Erythropoietin Production.- A. Introduction.- B. Model for the Control of Erythropoietin Production.- C. Hypoxia and Erythropoietin Production.- D. Adenosine and Erythropoietin Production.- References.- 4 The Mechanism of Action of Erythropoietin: Erythroid Cell Response.- A. Introduction.- B. Model Systems for Studying the Interaction of Erythropoietin with Erythroid Progenitor Cells.- C. Interaction of Other Growth and Development Factors with Erythroid Progenitor Cells.- D. The Erythroid Differentiation Program.- E. Signal Transduction in Erythroid Progenitor Cells.- F. Erythropoietin as a Competence or Progression Factor.- G. Conclusion.- References.- 5 The Arachidonic Acid Cascade and Erythropoiesis.- A. Introduction.- B. Evidence for the Roles of Arachidonic Acid Metabolism in Erythropoiesis.- C. Future Directions for Research.- References.- 6 Iron Deficiency and Megaloblastic Anemias.- A. Iron-Deficiency Anemia.- B. Megaloblastic Anemias.- References.- 7 Erythropoietin in the Anemia of End-Stage Renal Disease.- A. Assay of Erythropoietin.- B. Pathogenesis of the Anemia of Chronic Renal Failure.- C. Kidney Production of Erythropoietin.- D. Erythropoietin in Therapy of Renal Anemia.- E. Conclusions.- References.- 8 Humoral Control of Thrombocytopoiesis.- A. Introduction.- B. Model for Megakaryocytopoiesis.- C. Controlling Factors.- D. Other Factors Affecting Thrombocytopoiesis.- E. Clinical Aspects of Thrombopoietin.- F. Future of Thrombopoietin.- References.- 9 Arachidonic Acid Metabolism Platelets and Thromboembolic Disease.- A. Arachidonic Acid Metabolism.- B. Thromboembolic Disease.- C. Concluding Comments.- References.- 10 Chemical Agents That Inhibit Platelet Aggregation.- A. Introduction.- B. Platelet Physiology.- C. Platelet Structure.- D. Platelet Involvement in Thrombosis.- E. Platelet Responses.- F. Inhibition of Platelet Aggregation.- G. Conclusions.- References.- 11 Anticoagulants, Antithrombotic and Thrombolytic Agents.- A. Anticoagulants.- B. Thrombolytic Therapy.- C. Antithrombotic Therapy.- References.- 12 Granulocyte-Macrophage Growth Factors.- A. Introduction.- B. Historical Background.- C. Growth Factors.- D. Other Interleukins.- E. Inhibitors.- F. Cellular Production and Networking.- G. Microenvironment.- H. Conclusions.- References.- 13 Chemical Agents Which Suppress Myelopoiesis: Agranulocytosis and Leukemia.- A. Introduction.- B. Normal Marrow Cell Kinetics.- C. Pathophysiologic Mechanisms for Drug-Induced Neutropenia.- D. Neutropenia Associated with Cytotoxic Chemotherapeutic Agents.- E. Drug-Induced Myeloid Suppression.- F. Idiosyncratic Neutropenias.- G. Pseudoneutropenia.- H. Secondary Leukemia.- J. Conclusions.- References.- 14 Drugs Useful in the Chemotherapy of the Acute Leukemias.- A. Introduction.- B. Antimetabolites.- C. Drugs that Intercalate in DNA.- D. Podophyllotoxin Derivatives.- E. Vinca Alkaloids.- F. Alkylating/DNA Binding Agents.- G. Adrenal Glucocorticoids.- H. Enzymes.- J. Multidrug Resistance.- References.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
